Relationship between ZAP-70, IGHV mutation status, and the time from diagnosis to initial therapy in the subset of patients in the validation cohort with cytogenetic data (N = 323)
| Genetic characterization . | Concordant cases . | Discordant cases . | ||||||
|---|---|---|---|---|---|---|---|---|
| Total no. of pts . | ZAP-70−/M-IGHV, no. (%) . | ZAP-70+/U-IGHV, no. (%) . | P* . | Total no. of pts . | ZAP-70+/M-IGHV, no. (%) . | ZAP-70−/U-IGHV, no. (%) . | P* . | |
| 17p13q or 11q22 | 48 | 3 (6) | 45 (94) | < .001 | 23 | 2 (9) | 21 (91) | .034 |
| IGHV3-21 | 4 | 3 (75) | 1 (25) | .154 | 6 | 1 (17) | 5 (83) | .999 |
| Other | 167 | 77 (46) | 90 (54) | < .001 | 75 | 24 (32) | 51 (68) | .026 |
| Genetic characterization . | Concordant cases . | Discordant cases . | ||||||
|---|---|---|---|---|---|---|---|---|
| Total no. of pts . | ZAP-70−/M-IGHV, no. (%) . | ZAP-70+/U-IGHV, no. (%) . | P* . | Total no. of pts . | ZAP-70+/M-IGHV, no. (%) . | ZAP-70−/U-IGHV, no. (%) . | P* . | |
| 17p13q or 11q22 | 48 | 3 (6) | 45 (94) | < .001 | 23 | 2 (9) | 21 (91) | .034 |
| IGHV3-21 | 4 | 3 (75) | 1 (25) | .154 | 6 | 1 (17) | 5 (83) | .999 |
| Other | 167 | 77 (46) | 90 (54) | < .001 | 75 | 24 (32) | 51 (68) | .026 |
The distribution of cases according to the ZAP-70 expression and IGHV mutation status (concordant and discordant) and according to the presence or absence of additional genetic high-risk features, such as del11q22 or del17p13, or use of IGHV3–21, are listed.
ZAP-70 indicates zeta-associated protein of 70 kDa; M-IGHV, mutated IGHV; and U-IGHV, unmutated IGHV.
P values determined according to Fisher exact test.